Editas Medicine (EDIT) Non-Current Assets (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Non-Current Assets of $22.6 million for Q4 2025, down 56.69% year-over-year from $52.3 million in Q4 2024, and down 8.93% quarter-over-quarter from $24.9 million in Q3 2025.
Editas Medicine (EDIT) Non-Current Assets (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Non-Current Assets for 11 consecutive years, with $22.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets fell 56.69% year-over-year to $22.6 million; the TTM figure through Dec 2025 stood at $114.1 million (down 66.63% YoY), while the FY2025 annual figure was $22.6 million, down 56.69% from the prior year.
- Non-Current Assets eased to $22.6 million in Q4 2025 per EDIT's latest filing, from $24.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $170.2 million in Q4 2021 and bottomed at $22.6 million in Q4 2025.
- Historically, Non-Current Assets has averaged $105.8 million across 5 years, with a median of $122.8 million in 2022.
- Annual changes were most pronounced in 2021 — Non-Current Assets jumped 255.45% — and 2025, when it sank 71.78%.
- Editas Medicine's Non-Current Assets stood at $170.2 million in 2021, then slipped by 7.41% to $157.6 million in 2022, then rose by 0.48% to $158.3 million in 2023, then tumbled by 66.98% to $52.3 million in 2024, then sank by 56.69% to $22.6 million in 2025.
- Business Quant data shows EDIT's Non-Current Assets at $22.6 million in Q4 2025, $24.9 million in Q3 2025, and $27.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 22.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.64 Mn |
| Sep 30, 2025 | 24.86 Mn |
| Jun 30, 2025 | 27.79 Mn |
| Mar 31, 2025 | 38.81 Mn |
| Dec 31, 2024 | 52.27 Mn |
| Sep 30, 2024 | 56.43 Mn |
| Jun 30, 2024 | 98.45 Mn |
| Mar 31, 2024 | 134.79 Mn |
| Dec 31, 2023 | 158.32 Mn |
| Sep 30, 2023 | 146.05 Mn |
| Jun 30, 2023 | 100.98 Mn |
| Mar 31, 2023 | 139.65 Mn |
| Dec 31, 2022 | 157.57 Mn |
| Sep 30, 2022 | 104.40 Mn |
| Jun 30, 2022 | 119.46 Mn |
| Mar 31, 2022 | 126.08 Mn |
| Dec 31, 2021 | 170.17 Mn |
| Sep 30, 2021 | 149.41 Mn |
| Jun 30, 2021 | 139.59 Mn |
| Mar 31, 2021 | 147.98 Mn |